News
MEDP
568.36
+1.45%
8.15
Medpace (MEDP) Outperforms Broader Market: What You Need to Know
NASDAQ · 1h ago
PLSE Wins FDA IDE Approval to Launch nPulse AF Ablation Study Trial
NASDAQ · 9h ago
Revvity Advances AI-Driven Scientific Discovery With Signals Xynthetica
NASDAQ · 11h ago
ECL Boosts High-Tech Water Platform With Ovivo's Electronics Business
NASDAQ · 1d ago
Here's Why You Should Hold DaVita Stock in Your Portfolio for Now
NASDAQ · 1d ago
Here's Why You Should Retain CLOV Stock in Your Portfolio Now
NASDAQ · 1d ago
GEHC Expands Healthcare Access Through Indonesia MoH Partnership Deal
NASDAQ · 2d ago
Medpace Holdings Is Maintained at Underweight by Barclays
Dow Jones · 4d ago
Medpace Holdings Price Target Raised to $525.00/Share From $485.00 by Barclays
Dow Jones · 4d ago
Barclays Maintains Underweight on Medpace Hldgs, Raises Price Target to $525
Benzinga · 4d ago
BAX Highlights EMR-Integrated Smart Pumps Boost Patient Safety & Care
NASDAQ · 4d ago
MEDPACE HOLDINGS INC <MEDP.O>: BARCLAYS RAISES TARGET PRICE TO $525 FROM $485
Reuters · 4d ago
Medpace price target raised to $525 from $485 at Barclays
TipRanks · 4d ago
Weekly Report: what happened at MEDP last week (1208-1212)?
Weekly Report · 4d ago
Medpace Holdings (MEDP) Gets a Sell from Barclays
TipRanks · 4d ago
U.S. RESEARCH ROUNDUP-Applied Materials, Coca-Cola, Glacier Bancorp
Reuters · 4d ago
How Acquisition-Light Revenue Growth And EPS Leverage At Medpace Holdings (MEDP) Has Changed Its Investment Story
Simply Wall St · 5d ago
Evaluating Medpace (MEDP) After Strong Growth, Investor Support, and Aggressive Buybacks Fuel a Rerating
Simply Wall St · 6d ago
2 Profitable Stocks to Keep an Eye On and 1 We Find Risky
Barchart · 12/12 03:52
Is Medpace Still Attractive After Its Huge Multi Year Share Price Surge in 2025
Simply Wall St · 12/12 02:32
More
Webull provides a variety of real-time MEDP stock news. You can receive the latest news about Medpace Holdings through multiple platforms. This information may help you make smarter investment decisions.
About MEDP
Medpace Holdings, Inc. is a scientifically driven, global, full-service clinical contract research organization (CRO) providing phase I-IV clinical development services to the biotechnology, pharmaceutical and medical device industries. The Company partners with pharmaceutical, biotechnology, and medical device companies in the development and execution of clinical trials. The Company’s drug development services focus on full-service Phase I-IV clinical development services and include development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support. The Company also provides bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials. The Company’s operations are principally based in North America, Europe, and Asia.